The Congo's deadliest Ebola outbreak is a failure of incentives, not just virology

THE OUTBREAK of Ebola in the Democratic Republic of Congo (DRC) that began in May is now the second-deadliest in history. As of early August, 3,695 confirmed cases and 1,623 deaths give it a case-fatality ratio of 44%. It is also the fastest-spreading Ebola epidemic ever recorded: it passed 1,000 cases in 40 days, compared with approximately 235 days for the 2018-2020 outbreak that killed more than 2,200 people. Weekly cases peaked at 567 in the last week of July, according to the World Health Organisation (WHO). The outbreak is caused not by the Zaire ebolavirus, for which an effective vaccine and treatments exist, but by the Bundibugyo strain, one of the rarest ebolavirus species, which has caused just three documented outbreaks since its discovery in 2007 and has no licensed vaccine or therapy.

The surface question is virological: why is this strain proving so difficult to contain? The deeper question is institutional. The outbreak's scale is a function not only of a deadlier virus but of a health system that has been hollowed out, a response apparatus starved of funds, and a region where armed groups treat community engagement as a security threat. The outbreak is becoming deadlier because the incentives of the actors who should be stopping it point elsewhere.

Bundibugyo deserves its attention. Past outbreaks of this strain had case-fatality rates between 30% and 50%, as recorded by the WHO. The current figure of 44% sits in that range, which is disquieting in itself but is not inherently worse than what Zaire ebolavirus can produce-its fatality rate has ranged from 25% to 90% across different outbreaks. The danger is not the virus's intrinsic deadliness alone. It is the absence of tools. The ring-vaccination approach that brought the 2018-2020 DRC outbreak under control used an rVSV-ZEBOV vaccine developed in a marathon of emergency science; it does not protect against Bundibugyo. The Coalition for Epidemic Preparedness Innovations (CEPI), a public-private vaccine funder, has fast-tracked three experimental Bundibugyo candidates developed by IAVI, Moderna, and the University of Oxford's Serum Institute of India partner. None is licensed yet, and clinical deployment is months away at best.

This is where the system begins to creak. Even with a vaccine, Ebola response depends on three pillars: early detection through community surveillance, a trusted health workforce willing to engage populations, and the logistics to deliver care and safe burials. All three are failing.

The DRC has now suffered 17 Ebola outbreaks. That should have been enough to build durable local capacity. Instead the health system that underpins epidemic response has been eroded. Over the past year the American government, the world's largest donor of infectious-disease aid, sharply cut funding to Congo. Programs explicitly designed to safeguard against epidemics-surveillance networks, cold-chain supply for diagnostic kits, sanitation infrastructure, training for community health workers-were defunded, according to six people involved in or familiar with the efforts in the region, some of whom spoke to StatNews on condition of anonymity out of fear of retaliation. The result, as public-health insiders describe it, is a system that was supposed to detect outbreaks weeks before they became crises.

To be sure, aid cuts alone do not explain an outbreak of this size. Ebola has spread in war zones before, and the 2014-2016 West African epidemic killed more than 11,000 people in part because regional health systems were weaker than Congo's were. Yet the DRC of 2026 faces a different kind of deficit. The threat is not merely poverty. It is the deliberate destruction of state capacity.

Ituri province, the outbreak's epicentre, accounts for 88% of all confirmed cases and 82.6% of reported deaths, according to the WHO. It is home to Mongbwalu, a gold-mining town of 130,000 people where armed groups control territory and movement. The M23 rebellion, backed by neighbouring Rwanda (a charge Rwanda denies), has driven millions of displaced people across eastern Congo since 2022. Displacement creates the conditions for explosive transmission: crowded camps, broken contact-tracing networks, populations that have fled precisely because the state cannot protect them. Médecins Sans Frontières (MSF), a French-led aid group, called on 15 July for an "urgent scale-up" of the medical response after two months of unchecked spread.

Community distrust compounds the problem. In previous outbreaks, rumours that Ebola was a hoax, that treatment centres were death traps, and that government agents were deliberately infecting people delayed vaccination and care. Those conditions remain. Armed groups block health workers from entering their territory. Communities that have survived years of militia violence are sceptical of strangers in protective suits asking them to surrender their dead for burial. Contact tracing-the practice of following every person who has been in proximity to a case-works in places where there is security and trust, and collapses where there is neither.

The funding picture is worse. On 5 June, the WHO and the Africa Centres for Disease Control and Prevention launched a joint continental response plan seeking $518m. By mid-June, more than $910m had been pledged at a meeting of African heads of state and international partners. Less than $90m had been disbursed, underscoring the familiar gap between diplomatic generosity and operational delivery. Pledging-conference architectures are always vulnerable to this lag; but in the case of Congo the problem is structural. Pledges come from governments whose political incentives are to announce contributions in front of cameras. Disbursement requires bureaucracy, risk assessment, and a willingness to send funds into a conflict zone. The result is that the money exists in principle and is absent in practice.

There is a counter-argument worth taking seriously. Some might say that international actors cannot be expected to finance epidemic control in a sovereign state where armed groups actively undermine it, and where the government in Kinshasa has its own credibility problems. Aid fatigue is real, particularly in a world stretched by competing crises. The question of how much donor nations owe to states whose governments cannot guarantee security is not easily resolved.

Yet the framing of this as a problem of Congolese governance, or of African capacity, or of recipient-state responsibility, misses the incentive structure that governs global-health investment. The same cuts that hollowed out surveillance in Ituri also weakened the early-warning systems that prevent outbreaks from crossing borders. The WHO has already declared the outbreak a public health emergency of international concern, the highest level of alert. Cases have appeared in Uganda. American officials imposed travel restrictions on people from the affected region, closing the border to citizens and recent travellers while exempting American passport holders-a measure that says as much about domestic politics as about epidemiology. The outbreak's consequences will not stay contained within Congo's borders. A policy of retrenchment in one of the world's most fragile epidemic gateways is an actuarial miscalculation, not merely an ungenerous one.

The structural prescription follows from the analysis. The first task is to get existing money to the ground. The gap between pledges and disbursement is a bureaucratic failure, not a lack of resources. A wiser system would channel funds through mechanisms that can operate in conflict zones-MSF, local partners with community access, and security-aware logistics providers-rather than waiting for state channels that may not function. The second task is to build a Bundibugyo vaccine without delay. CEPI's fast-track of three candidates is the right response, but it must be paired with manufacturing capacity and regulatory pathways that can move at epidemic speed. The third task, longer-term, is to treat Congo's health system as strategic infrastructure, not as charity. The DRC has been the epicentre of Ebola for more than a decade. That is not an argument for perpetual dependency. It is an argument for investing in local institutions-laboratories, training programmes, community-health networks-that can survive political change and armed conflict.

The outbreak in Congo is becoming deadlier because the tools, trust and funding that made the 2018-2020 epidemic containable have been removed. A rarer virus has found a system that no longer expects it. That is not a coincidence. It is the predictable outcome of retrenchment in the face of an incentive to spend elsewhere. The cost of fixing it will be less than the cost of the next crisis.